Catalyst
Slingshot members are tracking this event:
Advaxis (ADXS) Announces Phase 2 GOG-0265 Results Evaluating Lead Candidate Axalimogene Filolisbac in Patients with Persistent/Recurrent Metastatic Carcinoma of the Cervix
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ADXS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 24, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Gog-0265, Lead Candidate, Axalimogene Filolisbac, Filolisbac, Persistent, Recurrent Ethmoid Sinus Obstruction, Metastatic Carcinoma Of The Cervix
